Traders should monitor the April 11 and April 15 presentations for any new efficacy or safety data from the SOL-1 trial, which could influence sentiment around AXPAXLI™'s regulatory and commercial potential. Absent data or approval, this filing is routine scientific communication.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $8.33entry
- T+1 · 8mo ago +1.92%α +1.84% · $8.49
- T+5 · 7mo ago +11.64%α +7.88% · $9.30
- T+20 · 7mo ago +10.56%α +0.84% · $9.21
- T+60 · 5mo ago +18.85%α +5.47% · $9.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocular Therapeutix announced upcoming presentations of Phase 3 data for its investigational therapy AXPAXLI™ (OTX-TKI) in wet AMD at major ophthalmology conferences in April 2026. The data disclosures are part of ongoing scientific dissemination, not a regulatory approval or clinical trial result announcement.
Key Facts
- Ocular Therapeutix will present SOL-1 Phase 3 data for AXPAXLI™ (OTX-TKI) in wet AMD at the Vit-Buckle Society meeting on April 11, 2026.
- Additional presentations on diabetic retinal disease and wet AMD will occur at CNO 2026 in Buenos Aires from April 15–17, 2026.
- AXPAXLI™ is an axitinib intravitreal hydrogel in Phase 3 trials for wet AMD and diabetic retinal disease, including NPDR.
- No new clinical data, FDA decision, or commercial update was released, this is a schedule of upcoming scientific presentations.
Financial Impact
Minimal near-term financial impact; no revenue or cost implications disclosed
Risk Factors
- Data presented at the conferences could reveal safety concerns or lower-than-expected efficacy for AXPAXLI™
- Failure to show superiority over existing anti-VEGF therapies could limit commercial adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266467 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers